LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Oct. 31, 2017 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced company presentations at the following conferences taking place in November:
Gene Therapy for Rare Disorders, November 1 -2, 2017, at the Hilton London Olympia in London, United Kingdom.
Life Science Summit by Defined Health, November 1 - 2, 2017, at 10 on the Park at Time Warner Center in New York City, NY.
Huntington's disease Study Group, November 2 - 4, 2017, at the at the Hyatt Regency Conference Center in Denver, Co.
10th Global Forum on Research and Treatment Products for Bleeding Disorders, November 8 - 10, 2017, at the Marriott Château Champlain hotel in Montreal, Canada.
2017 BioMAN Summit on Commercialization of Cell and Gene Therapy Products: The Impact of Critical Choices, November 14- 15, 2017, at the Boston Marriott Cambridge in Boston, MA.
Evercore ISI Inaugural Biopharma Catalyst/Deep Dive Conference, November 29 - 30, 2017, at the Boston Harbor Hotel in Boston, MA.
Barclays Gene Editing & Gene Therapy Summit Conference, November 30, 2017, at Barclays offices at 745 Seventh Avenue in New York City, NY.
About uniQure
uniQure is delivering on the promise of gene therapy - single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with hemophilia, Huntington's disease and cardiovascular diseases. www.uniQure.com
uniQure Contacts:
For Investors:
Maria E. Cantor
Direct: 339-970-7536
Mobile: 617-680-9452
m.cantor@uniQure.com
Eva M. Mulder
Direct: +31 20 240 6103
Mobile: +31 6 52 33 15 79
e.mulder@uniQure.com
For Media:
Tom Malone
Direct: 339-970-7558
Mobile: 339-223-8541
t.malone@uniQure.com
Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.